Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


From Beginning To End, FDA Transparency Weighed On Sharfstein’s Mind

Executive Summary

As a lead player in FDA’s Transparency Initiative, outgoing Principal Deputy Commissioner Joshua Sharfstein helmed a task force that, on his penultimate day at the agency, unveiled a slew of measures to increase industry access to pertinent regulatory information.

You may also be interested in...

A Return Trip For Kessler At US FDA? It Wouldn’t Be The First Time It’s Happened

Two physicians experienced in agency affairs and operations, former commissioner David Kessler and former principal deputy commissioner Joshua Sharfstein, are reportedly finalists to head Biden’s FDA.

Roxane's Redesigned Morphine Carton Reflects Orderly Rollout After Safety Concern

FDA allows existing stock to be used up over the course of a year after the new color-coded container for the high-potency product was approved.

FDA’s Unapproved Drugs Policy Draws Legal, Regulatory Responses From Lannett, To Little Success

Generic drug maker Lannett Co. is taking a two-pronged approach in responding to FDA’s unapproved drugs initiative, seeking regulatory approval of a previously unapproved opioid product while simultaneously suing the agency in federal court.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts